Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 28, 2021; 27(16): 1816-1827
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1816
Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1816
Table 1 The time elapsed from surgery to completion of the questionnaires among different surgical procedures
| Median (IQR), yr | |
| Total gastrectomy | 3 (2-4) |
| Subtotal distal gastrectomy | 3 (2-4) |
| Billroth II reconstruction | 3 (1-4) |
| Roux-en-Y reconstruction | 2.5 (1-4) |
Table 2 Baseline characteristics of patients eligible for inclusion (n = 234)
| Respondents (n = 116) | Non-respondents (n = 118) | P value | |
| Gender, n (%) | 0.192 | ||
| Male | 63 (54.3) | 74 (62.7) | |
| Female | 53 (45.7) | 44 (37.3) | |
| Age at surgery (yr, median, IQR) | 66 (58-74) | 72 (63-78) | 0.016 |
| Performed procedure, n (%) | 0.299 | ||
| Total gastrectomy | 43 (37.1) | 55 (46.6) | |
| Distal-Billroth II | 26 (22.4) | 20 (16.9) | |
| Distal-Roux-Y | 47 (40.5) | 43 (36.4) | |
| Postoperative complications, n (%) | |||
| Yes | 28 (24.1) | 38 (32.2) | 0.170 |
| TNM stage, n (%) | 0.001 | ||
| 0 | 3 (2.6) | 4 (3.4) | |
| I | 52 (44.8) | 25 (21.2) | |
| II | 32 (27.6) | 36 (30.5) | |
| III | 29 (25.0) | 53 (44.9) |
Table 3 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) questionnaire scores by the type of resection (Mann-Whitney U test)
| Subtotal gastrectomy (n = 73) | Total gastrectomy (n = 43) | P value | |||
| mean (SD) | Median (IQR) | mean (SD) | Median (IQR) | ||
| Functional scales | |||||
| Physical functioning | 79.9 (21.4) | 87 (67-100) | 80.3 (19.5) | 87 (73-100) | 0.954 |
| Role functioning | 80.2 (26.7) | 100 (67-100) | 77.9 (26.1) | 83 (67-100) | 0.509 |
| Cognitive functioning | 81.9 (21.6) | 83 (67-100) | 82.9 (19.7) | 83 (67-100) | 0.842 |
| Emotional functioning | 82.1 (20.5) | 92 (75-100) | 76.1 (21.5) | 79 (58-96) | 0.116 |
| Social functioning | 81.5 (22.5) | 83 (67-100) | 73.7 (26) | 83 (50-100) | 0.115 |
| Symptoms | |||||
| Dyspnoea | 10.5 (22.1) | 0 (0-0) | 10.8 (21.5) | 0 (0-0) | 0.869 |
| Insomnia | 28.7 (29.1) | 33 (0-33) | 27.8 (28.1) | 33 (0-33) | 0.917 |
| Appetite loss | 10 (19.7) | 0 (0-0) | 12.3 (20.6) | 0 (0-33) | 0.489 |
| Nausea/vomiting | 10.7 (17.4) | 0 (0-17) | 4.7 (9.8) | 0 (0-0) | 0.079 |
| Constipation | 10.5 (22.1) | 0 (0-0) | 6.9 (13.6) | 0 (0-0) | 0.665 |
| Diarrhoea | 13.6 (22.7) | 0 (0-33) | 19.3 (24.4) | 0 (0-33) | 0.141 |
| Fatigue | 30.5 (23.3) | 22 (17-33) | 34.2 (23.4) | 33 (22-50) | 0.263 |
| Pain | 18.3 (22.4) | 17 (0-33) | 17.9 (21.6) | 17 (0-33) | 0.906 |
| Financial problems | 16.4 (26.7) | 0 (0-33) | 27.1 (32.8) | 0 (0-67) | 0.069 |
| Global health status | 66.6 (22.9) | 67 (50-83) | 67.4 (19.9) | 67 (58-83) | 0.846 |
Table 4 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) questionnaire scores by the type of reconstruction (Mann-Whitney U test)
| Billroth II (n = 26) | Roux-Y (n = 47) | P value | |||
| mean (SD) | Median (IQR) | mean (SD) | Median (IQR) | ||
| Functional scales | |||||
| Physical functioning | 73.1 (23) | 73.5 (53-93) | 83.7 (19.6) | 92 (73-100) | 0.038 |
| Role functioning | 70.5 (31.4) | 67 (50-100) | 85.5 (22.4) | 100 (67-100) | 0.034 |
| Cognitive functioning | 76.9 (26.3) | 83 (67-100) | 84.7 (18.3) | 83 (83-100) | 0.301 |
| Emotional functioning | 74.9 (27.7) | 83 (58-100) | 86 (14) | 92 (75-100) | 0.220 |
| Social functioning | 79.5 (25.9) | 83 (67-100) | 82.6 (20.5) | 83 (67-100) | 0.792 |
| Symptoms | |||||
| Dyspnoea | 16.7 (30.3) | 0 (0-33) | 7 (15.4) | 0 (0-0) | 0.285 |
| Insomnia | 37.1 (33.2) | 33 (0-67) | 24 (25.8) | 33 (0-33) | 0.102 |
| Appetite loss | 12.8 (25.1) | 0 (0-33) | 8.4 (16.2) | 0 (0-0) | 0.651 |
| Nausea/vomiting | 15.4 (22.1) | 0 (0-33) | 8.1 (13.8) | 0 (0-17) | 0.194 |
| Constipation | 19.2 (31.5) | 0 (0-33) | 5.6 (12.5) | 0 (0-0) | 0.054 |
| Diarrhoea | 14.1 (31.6) | 0 (0-0) | 13.3 (16.4) | 0 (0-33) | 0.200 |
| Fatigue | 41 (28.6) | 33 (22-67) | 24.6 (17.5) | 22 (17-33) | 0.028 |
| Pain | 28.9 (28.1) | 17 (0-50) | 12.4 (16.1) | 0 (0-17) | 0.010 |
| Financial problems | 19.2 (28.6) | 0 (0-33) | 14.8 (25.8) | 0 (0-33) | 0.510 |
| Global health status | 68.2 (24.7) | 67 (50-83) | 65.7 (22) | 67 (50-83) | 0.635 |
Table 5 Surgery type among different stages of the disease
| Total gastrectomy, n (%) | Subtotal-Billroth II, n (%) | Subtotal-Roux-Y, n (%) | P value | |
| Stage | 0.002 | |||
| 0 | 4 (4.1) | 3 (6.5) | 0 (0) | |
| I | 25 (25.5) | 14 (30.4) | 38 (42.2) | |
| II | 26 (26.5) | 10 (21.7) | 32 (35.6) | |
| III | 43 (43.9) | 19 (41.3) | 20 (22.2) |
Table 6 Association between surgery type and global health status scores adjusted for demographic and clinical characteristics
| β (P value) | |
| Male | -0.11 (0.229) |
| Age (yr) | -0.05 (0.625) |
| Total vs Billroth II | -0.001 (0.990) |
| Roux-Y vs Billroth II | -0.08 (0.492) |
| Postoperative complications-yes | -0.15 (0.116) |
| Stage II/III vs 0/I | -0.21 (0.029) |
Table 7 Association between surgery type and scores on functional scales adjusted for demographic and clinical characteristics
| Emotional | Social | Role | Physical | Cognitive | ||||||
| β | P value | β | P value | β | P value | β | P value | β | P value | |
| Male | 0.01 | 0.901 | 0.10 | 0.254 | 0.09 | 0.334 | 0.16 | 0.089 | 0.04 | 0.666 |
| Age (yr) | 0.09 | 0.343 | 0.05 | 0.557 | 0.08 | 0.379 | -0.09 | 0.343 | 0.18 | 0.054 |
| Total vs Billroth II | 0.04 | 0.729 | -0.11 | 0.343 | 0.15 | 0.199 | 0.15 | 0.201 | 0.16 | 0.194 |
| Roux-Y vs Billroth II | 0.24 | 0.041 | 0.04 | 0.763 | 0.24 | 0.034 | 0.23 | 0.048 | 0.17 | 0.154 |
| Postoperative complications yes | -0.03 | 0.730 | -0.13 | 0.150 | -0.15 | 0.101 | -0.10 | 0.292 | 0.01 | 0.915 |
| Saage II/III vs 0/I | -0.17 | 0.062 | -0.20 | 0.031 | -0.27 | 0.003 | -0.16 | 0.079 | -0.09 | 0.324 |
Table 8 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire gastric cancer-specific module (QLQ STO-22) questionnaire scores by the type of resection (Mann-Whitney U test)
| Subtotal gastrectomy (n = 60) | Total gastrectomy (n = 51) | P value | |||
| mean (SD) | Median (IQR) | mean (SD) | Median (IQR) | ||
| Dysphagia | 11.1 (15.8) | 11 (0-11) | 17.2 (17.1) | 11 (0-33) | 0.020 |
| Pain | 19.7 (17.9) | 17 (8-33) | 23.3 (20.9) | 17 (8-33) | 0.477 |
| Reflux | 16 (20.9) | 11 (0-22) | 22.7 (23.6) | 11 (0-44) | 0.089 |
| Eating restrictions | 14.7 (17.4) | 8 (0-17) | 21.6 (18.2) | 17 (8-33) | 0.017 |
| Anxiety | 33.1 (23.4) | 33 (17-44) | 31.4 (25.8) | 22 (11-44) | 0.591 |
| Dry mouth | 24.1 (28.5) | 33 (0-33) | 24.7 (28.3) | 33 (0-33) | 0.871 |
| Taste | 6.4 (18.1) | 0 (0-0) | 11.6 (21.7) | 0 (0-33) | 0.109 |
| Body image | 18.7 (29.9) | 0 (0-33) | 20.1 (27.4) | 0 (0-33) | 0.567 |
| Hair loss | 16.4 (27.9) | 0 (0-33) | 8.7 (20.9) | 0 (0-0) | 0.124 |
Table 9 European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire gastric cancer-specific module (QLQ STO-22) questionnaire scores by the type of reconstruction (Mann-Whitney U test)
| Billroth II (n = 18) | Roux-Y (n = 42) | P value | |||
| mean (SD) | Median (IQR) | mean (SD) | Median (IQR) | ||
| Dysphagia | 15.8 (22.3) | 5.5 (0-22) | 8.5 (10.2) | 11 (0-11) | 0.526 |
| Pain | 24.3 (23.9) | 17 (8-33) | 17.2 (13.3) | 17 (8-25) | 0.471 |
| Reflux | 28.5 (26.3) | 22 (0-44) | 9.1 (13) | 0 (0-11) | 0.001 |
| Eating restrictions | 22.3 (22.8) | 17 (0-42) | 10.4 (11.7) | 8 (0-17) | 0.069 |
| Anxiety | 36.6 (26.9) | 33 (22-55) | 31.2 (21.3) | 33 (11-44) | 0.541 |
| Dry mouth | 23 (26.3) | 33 (0-33) | 24.7 (29.9) | 0 (0-33) | 0.965 |
| Taste | 11.5 (26.6) | 0 (0-0) | 3.5 (10.3) | 0 (0-0) | 0.247 |
| Body image | 26.8 (36.5) | 0 (0-33) | 14.1 (24.8) | 0 (0-33) | 0.127 |
| Hair loss | 14.1 (27) | 0 (0-33) | 17.7 (28.6) | 0 (0-33) | 0.541 |
- Citation: Grosek J, Zavrtanik H, Tomažič A. Health-related quality of life after curative resection for gastric adenocarcinoma. World J Gastroenterol 2021; 27(16): 1816-1827
- URL: https://www.wjgnet.com/1007-9327/full/v27/i16/1816.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i16.1816